A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Weiss, M [1 ]
Maslak, P [1 ]
Megherian, L [1 ]
Scheinberg, D [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3131 / 3131
页数：1
相关论文
共 50 条
  • [41] Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Moore, Dominic
    McKinnon, Karen P.
    Wilkinson, Alec D.
    Mukhopadhyay, Rupkatha
    Mazziotta, Francesco
    Knaus, Hanna A.
    Foster, Matthew C.
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Webster, Jonathan A.
    Prince, Gabrielle T.
    DeZern, Amy E.
    Smith, B. Douglas
    Levis, Mark J.
    Montgomery, Nathan D.
    Luznik, Leo
    Serody, Jonathan S.
    Gojo, Ivana
    [J]. BLOOD CANCER DISCOVERY, 2021, 2 (06): : 616 - 629
  • [42] Idarubicin, high dose etoposide and high dose Ara-C (IDEA) treatment of high risk acute leukemia: A randomized study of schedule dependency of etoposide
    Johnston, L
    Damon, L
    Ries, C
    Rugo, H
    Linker, C
    [J]. BLOOD, 1996, 88 (10) : 855 - 855
  • [43] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [44] Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS).
    Yee, KWL
    Cortes, J
    Garcia-Manero, G
    Verstovsek, S
    Ferrajoli, A
    Wierda, WG
    Thomas, D
    Faderl, S
    King, I
    O'Brien, SM
    Sznol, M
    Giles, FJ
    [J]. BLOOD, 2005, 106 (11) : 311B - 311B
  • [45] HIGH-DOSE ARA-C AND ETOPOSIDE IN THE TREATMENT OF REFRACTORY OR RELAPSING ACUTE-LEUKEMIA
    FREUND, M
    LINK, H
    DIEDRICH, H
    WILKE, JJ
    SCHMOLL, HJ
    POLIWODA, H
    [J]. BLUT, 1987, 55 (04): : 215 - 215
  • [46] Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia
    Sung, WJ
    Kim, DH
    Sohn, SK
    Kim, JG
    Baek, JH
    Jeon, SB
    Moon, JH
    Ahn, BM
    Lee, KB
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (10) : 612 - 616
  • [47] A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)
    Krauter, Jurgen
    Schlenk, Richard F.
    Schaich, Markus
    Bouscary, Didier
    Dombret, Herve
    Winiger, Ivo J.
    Squier, Margaret
    Bengoudifa, Bourras-Rezki
    Ottmann, Oliver G.
    [J]. BLOOD, 2010, 116 (21) : 1356 - 1356
  • [48] High-dose ara-C in older adults with acute leukemia
    Herzig, RH
    [J]. LEUKEMIA, 1996, 10 : S10 - S11
  • [49] DRUG SENSITIVITY TEST FOR PATIENTS WITH ACUTE-LEUKEMIA ON HIGH-DOSE ARA-C THERAPY
    MOMPARLER, RL
    ONETTO, N
    MOMPARLER, LF
    GYGER, M
    LECLERC, JM
    RIVARD, GE
    [J]. SEMINARS IN ONCOLOGY, 1985, 12 (02) : 31 - 33
  • [50] MAMSA + HIGH-DOSE ARA-C IN ACUTE-LEUKEMIA
    ZITTOUN, R
    [J]. INVESTIGATIONAL NEW DRUGS, 1984, 2 (01) : 110 - 110
12345